Avelumab is named as an intervention in 13 current clinical trials in our USA, UK, China and Ireland registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is EMD Serono Research & Development Institute, Inc (2). The most-studied condition is Metastatic Urothelial Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Urothelial Cancer | 2 |
| NSCLC | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Metastatic Renal Cell Carcinoma | 1 |
| Stage III Renal Cell Cancer AJCC v8 | 1 |
| Stage IV Renal Cell Cancer AJCC v8 | 1 |
| Unresectable Renal Cell Carcinoma | 1 |
| Solid Tumors | 1 |
| Neoplasm Malignant | 1 |
| Renal Cell Carcinoma | 1 |
| Hormone Receptor Positive Breast Carcinoma | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Advanced Malignancies | 1 |
| Ovarian Cancer | 1 |
| Urothelial Cancer | 1 |
| Solid Tumor, Adult | 1 |
| Non-Hodgkin Lymphoma, Adult | 1 |
| Myelofibrosis | 1 |
| Locally Advanced or Metastatic Urothelial Carcinoma | 1 |
| Melanoma | 1 |
| Breast Cancer Metastatic | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Cancer | 1 |
| Cutaneous Melanoma | 1 |
| Small Cell Lung Cancer | 1 |
| Urothelial Carcinoma | 1 |
| HPV-Related Carcinoma | 1 |
| HPV-Related Cervical Carcinoma | 1 |
| HPV-Related Anal Squamous Cell Carcinoma | 1 |
| HPV-Related Penile Squamous Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| EMD Serono Research & Development Institute, Inc. | 2 |
| NRG Oncology | 1 |
| Gilead Sciences | 1 |
| BicycleTx Limited | 1 |
| Exelixis | 1 |
| Pfizer | 1 |
| iOnctura | 1 |
| TILT Biotherapeutics Ltd. | 1 |
| Oncolytics Biotech | 1 |
| Aulos Bioscience, Inc. | 1 |
| ImmunityBio, Inc. | 1 |
| Transgene | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 11 | 1 |
| Clinical trials in UK | 7 | 0 |
| Clinical trials in China | 2 | 0 |
| Clinical trials in Ireland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
13 current trials in our USA, UK, China and Ireland registers name Avelumab as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 13 trials are recruiting: 1 with sites in USA and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
EMD Serono Research & Development Institute, Inc (2), NRG Oncology (1), Gilead Sciences (1) and BicycleTx Limited (1), among 12 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Avelumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Avelumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avelumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.